Modafinil
- Generic Name
- Modafinil
- Brand Names
- Provigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 68693-11-8
- Unique Ingredient Identifier
- R3UK8X3U3D
- Background
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...
- Indication
To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
- Associated Therapies
- -
Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia
- Conditions
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 44
- Registration Number
- NCT03772314
- Locations
- 🇺🇸
Emory Sleep Center, Atlanta, Georgia, United States
Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 343
- Registration Number
- NCT03621761
- Locations
- 🇺🇸
The University of Washington, Seattle, Washington, United States
🇺🇸The University of Michigan, Ann Arbor, Michigan, United States
Modafinil's Effects on Cognition in Remitted MDD
- Conditions
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 9
- Registration Number
- NCT03620253
- Locations
- 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
Modafinil Effects on EEG Biomarkers of Reward and Motivation
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 23
- Registration Number
- NCT03616717
- Locations
- 🇺🇸
University of California, San Diego; Clinical Teaching Facilities, Hillcrest, San Diego, California, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT03522506
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Touchscreen-based Cognitive Tests in Healthy Volunteers
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- University of Eastern Finland
- Target Recruit Count
- 16
- Registration Number
- NCT03469089
- Locations
- 🇫🇮
University of Eastern Finland, Clinical Research Centre, Brain Research Unit, Kuopio, Finland
Modafinil for the Treatment of Alcohol Use Disorders
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- The Mind Research Network
- Target Recruit Count
- 12
- Registration Number
- NCT03424681
- Locations
- 🇺🇸
Mind Research Network, Albuquerque, New Mexico, United States
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 141
- Registration Number
- NCT03185065
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Theranexus
- Target Recruit Count
- 20
- Registration Number
- NCT03182413
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 118
- Registration Number
- NCT02896712
- Locations
- 🇺🇸
UTHealth Center for Neurobehavioral Research on Addiction, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.